(0.13%) 5 138.25 points
(0.08%) 38 472 points
(0.22%) 17 885 points
(-0.26%) $83.63
(1.72%) $1.956
(0.11%) $2 349.80
(0.41%) $27.65
(1.46%) $935.60
(-0.07%) $0.934
(-0.19%) $11.00
(-0.19%) $0.799
(1.28%) $93.05
Live Chart Being Loaded With Signals
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations...
Stats | |
---|---|
Dagens volum | 762 848 |
Gjennomsnittsvolum | 1.17M |
Markedsverdi | 41.88M |
EPS | $0 ( 2024-02-21 ) |
Last Dividend | $7.15 ( 1993-10-21 ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.20 |
ATR14 | $0.00100 (1.89%) |
Prescient Therapeutics Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Prescient Therapeutics Økonomi
Annual | 2023 |
Omsetning: | $2.43M |
Bruttogevinst: | $2.43M (99.91 %) |
EPS: | $-0.00960 |
FY | 2023 |
Omsetning: | $2.43M |
Bruttogevinst: | $2.43M (99.91 %) |
EPS: | $-0.00960 |
FY | 2022 |
Omsetning: | $1.89M |
Bruttogevinst: | $1.89M (99.93 %) |
EPS: | $-0.00790 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.00680 |
Financial Reports:
No articles found.
Prescient Therapeutics Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $5.72 | 1990-10-25 |
Last Dividend | $7.15 | 1993-10-21 |
Next Dividend | $0 | N/A |
Payout Date | 1993-12-31 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $12.87 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.22 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
YAL.AX | Ex Dividend Knight | 2023-09-05 | Annually | 0 | 0.00% | |
FGG.AX | Ex Dividend Junior | 2023-10-05 | Annually | 0 | 0.00% | |
PMV.AX | Ex Dividend Knight | 2023-06-20 | Semi-Annually | 0 | 0.00% | |
ARG.AX | Ex Dividend Knight | 2023-08-25 | Semi-Annually | 0 | 0.00% | |
IFL.AX | Ex Dividend Junior | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
SDG.AX | Ex Dividend Knight | 2023-10-24 | Quarterly | 0 | 0.00% | |
CCP.AX | Ex Dividend Knight | 2023-09-18 | Annually | 0 | 0.00% | |
MCY.AX | Ex Dividend Knight | 2023-09-13 | Semi-Annually | 0 | 0.00% | |
TGF.AX | Ex Dividend Junior | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
CUV.AX | Ex Dividend Knight | 2023-09-05 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -2.49 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.313 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.318 | 1.500 | -4.65 | -6.97 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 10.26 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 9.96 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.08 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.00952 | 2.00 | -0.00317 | -0.00635 | [0 - 30] |
freeCashFlowPerShareTTM | -0.00952 | 2.00 | -0.00476 | -0.00952 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -3.71 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.126 | 0.800 | -2.50 | -1.996 | [0.5 - 2] |
Total Score | -0.920 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.51 | 1.000 | -0.658 | 0 | [1 - 100] |
returnOnEquityTTM | -0.318 | 2.50 | -2.99 | -6.97 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.00952 | 2.00 | -0.00317 | -0.00952 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.00952 | 2.00 | -0.00317 | -0.00635 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.911 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -2.46 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.81 |
Prescient Therapeutics
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.